Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,621 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
Interventions: IRX-101, Control; Drug
Lead sponsor: iRenix Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration
Interventions: ABF-101, Placebo; Drug
Lead sponsor: Aptabio Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stargardt Disease, Macular Atrophy
Interventions: Emixustat; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Retinitis Pigmentosa
Interventions: Argus II; Device
Lead sponsor: University of California, Santa Barbara; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Santa Barbara, California • Baltimore, Maryland • Ann Arbor, Michigan

Conditions: Atrophy, Geographic
Interventions: GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related)
Interventions: Anterior Chamber (AC) Tap; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Macular Edema
Interventions: Infliximab (intravitreal, 2.0mg/0.05ml); Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Geographic Atrophy
Interventions: FCFD4514S, sham; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years to 89 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 30
States / cities: Tucson, Arizona • Beverly Hills, California • San Francisco, California + 26 more

Conditions: Retinoblastoma, Melanoma, Sarcoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Years and older
Enrollment: 2,136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2024
U.S. locations: 4
States / cities: Bethesda, Maryland • Boston, Massachusetts • New York, New York + 1 more

Conditions: Mild Cognitive Impairment
Interventions: Octagam 10%; Biological
Lead sponsor: Sutter Health; Other
Eligibility: 50 Years to 84 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Retinitis Pigmentosa
Interventions: Electro-acupuncture, Laser Acupuncture, Transcorneal Electrical Stimulation, Sham Electro-acupuncture, Sham laser acupuncture, Sham transcorneal electrical stimulation; Device
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Neovascular (Wet) Age-related Macular Degeneration
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,079 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions: Surgical implantation of the CPCB-RPE1 implant; Device
Lead sponsor: Regenerative Patch Technologies, LLC; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 5
States / cities: Huntington Beach, California • Los Angeles, California • Lemont, Illinois + 2 more

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions: APL-2, Pegcetacoplan; Drug
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 5
States / cities: Bakersfield, California • Oxnard, California • Austin, Texas + 2 more

Conditions: Macular Degeneration
Interventions: ranibizumab; Drug
Lead sponsor: Steven R. Sanislo; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: San Francisco, California • Stanford, California

Conditions: Inflammation
Interventions: Intravitreal Ketorolac; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Geographic Atrophy, Age-Related Macular Degeneration
Interventions: OcuMet Beacon; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 50 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Macular Degeneration
Interventions: BI 754132; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Beverly Hills, California • Pensacola, Florida • Winter Haven, Florida + 5 more

Conditions: Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
Interventions: Pistachio Group; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia, Geographic Atrophy
Interventions: Retinal imaging; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 7 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Age-Related Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 55 Years to 120 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Macular Degeneration
Interventions: pazopanib, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Glendale, California

Conditions: Age-Related Maculopathy
Interventions: RN6G, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 60 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 83
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more

Search by objective public record fields.

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

The Perceptual Experience of Argus II Users

Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers

Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy

Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema

A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy

Retinoblastoma Biomarker Study

Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease

Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

Lucentis in Advanced Macular Degeneration

Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study

Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Pistachios and Neural Macular Pigment

High Resolution Retinal Imaging

AMD Ryan Initiative Study (ARIS)

A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers

Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration